Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

IMNM

Immunome Inc

Nov 27 • 04:00PM ET

13.47

Dollar change +1.94
Percentage change 16.83	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN MRNA NVAX SRPT NTLA CRSP PFE GILD BNTX BEAM

| Held by: VTI IWM XBI VXF IWO DWAS SCHA VTWO VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-8.12	Insider Own	18.69%	Shs Outstand	62.42M	Perf Week	44.37%
Market Cap	840.76M	Forward P/E	-	EPS next Y	-3.00	Insider Trans	1.09%	Shs Float	50.75M	Perf Month	10.41%
Income	-305.35M	PEG	-	EPS next Q	-0.66	Inst Own	82.31%	Short Float	21.02%	Perf Quarter	-11.61%
Sales	10.13M	P/S	83.00	EPS this Y	18.60%	Inst Trans	9.17%	Short Ratio	14.25	Perf Half Y	-8.43%
Book/sh	3.56	P/B	3.79	EPS next Y	31.59%	ROA	-174.46%	Short Interest	10.67M	Perf Year	75.62%
Cash/sh	3.85	P/C	3.50	EPS next 5Y	-	ROE	-276.36%	52W Range	6.93 - 30.96	Perf YTD	25.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.48%	ROI	-140.47%	52W High	-56.49%	Beta	1.77
Dividend TTM	-	Quick Ratio	6.17	Sales past 5Y	0.00%	Gross Margin	82.58%	52W Low	94.37%	ATR (14)	0.92
Dividend Ex-Date	-	Current Ratio	6.17	EPS Y/Y TTM	-337.50%	Oper. Margin	-3068.19%	RSI (14)	62.95	Volatility	9.29% 7.70%
Employees	55	Debt/Eq	0.01	Sales Y/Y TTM	-0.62%	Profit Margin	-3014.59%	Recom	1.00	Target Price	30.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-119.69%	Payout	-	Rel Volume	1.85	Prev Close	11.53
Sales Surprise	27.12%	EPS Surprise	-41.46%	Sales Q/Q	-18.37%	Earnings	Nov 13 AMC	Avg Volume	748.88K	Price	13.47
SMA20	17.44%	SMA50	8.90%	SMA200	-14.45%	Trades		Volume	1,382,845	Change	16.83%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Overweight	$30
May-31-24	Initiated	Piper Sandler	Overweight	$27
Apr-30-24	Initiated	JP Morgan	Overweight	$24
Apr-15-24	Initiated	Guggenheim	Buy	$35
Jan-29-24	Initiated	Leerink Partners	Outperform	$30
Dec-19-23	Initiated	Wedbush	Outperform	$12
Oct-29-21	Initiated	Cantor Fitzgerald	Overweight	$35

Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
04:05PM	Loading…
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%
Oct-30-24 08:30AM	Immunome Advances with Strategic Asset Acquisition and Agreement (TipRanks)
Oct-29-24 08:00AM	Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 (Business Wire)
Oct-18-24 08:00AM	Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium (Business Wire)
Oct-08-24 08:05AM	Immunome Appoints Roee Shahar as Executive Vice President, Commercial (Business Wire)
08:00AM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-24 07:00AM	Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (Business Wire) +8.57%
Aug-29-24 08:00AM	Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-20-24 03:26PM	Immunome Stock Sees RS Rating Jump To 91 (Investor's Business Daily) +6.36%
Aug-12-24 05:15PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.04%
04:01PM	Loading…
04:01PM	Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-25-24 08:00AM	Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities (Business Wire) +5.67%
07:30AM	Nectin Therapeutics Licenses Novel Antibodies to Immunome (PR Newswire)
Jul-09-24 07:00AM	STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors (GlobeNewswire)
Jun-27-24 08:00AM	Immunome Appoints Phil Tsai as Chief Technical Officer (Business Wire)
May-22-24 02:05PM	Hedge Fund and Insider Trading News: David Tepper, Stanley Druckenmiller, Oaktree Capital Management, Odey Asset Management, ProFrac Holding Corp. (ACDC), Immunome Inc (IMNM), and More (Insider Monkey) +5.64%
May-21-24 07:01PM	Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares (GuruFocus.com)
May-20-24 11:14AM	Immunome Completes Purchase of Antibodies From Atreca (MT Newswires)
08:00AM	Immunome Announces Completion of Purchase of Assets from Atreca (Business Wire)
May-17-24 08:51AM	Immunome Appoints Max Rosett as CFO (MT Newswires)
08:00AM	Immunome Announces Promotion of Max Rosett to Chief Financial Officer (Business Wire)
May-14-24 01:54PM	IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.70%
09:10AM	Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Immunome Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:00AM	Immunome to Present at 2024 Bank of America Healthcare Conference (Business Wire)
08:00AM	Loading…
May-02-24 08:00AM	Immunome Appoints Kinney Horn as Chief Business Officer (Business Wire)
Apr-30-24 07:29AM	--JPMorgan Starts Immunome With Overweight Rating, $24 Price Target (MT Newswires)
Apr-26-24 10:00AM	Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-25-24 08:26AM	Immunome Appoints Sandra M. Swain to Board of Directors (Business Wire)
Apr-05-24 08:00AM	Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-28-24 11:53PM	IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.41%
04:02PM	Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets (Business Wire)
Mar-26-24 08:00AM	Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala (Business Wire) +5.79%
08:00AM	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome (GlobeNewswire)
Mar-18-24 05:44AM	Arrayjets ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies (Business Wire)
Mar-07-24 08:00AM	Immunome to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Mar-04-24 07:00AM	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-01-24 08:00AM	Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference (Business Wire) +5.17%
Feb-20-24 08:15AM	Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (Business Wire) -10.99%
08:00AM	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors (GlobeNewswire)
Feb-16-24 04:05PM	Immunome Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +14.74%
Feb-13-24 10:38PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire)
04:05PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Feb-07-24 08:34AM	Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up (Zacks) +7.83%
Feb-06-24 09:20AM	Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks (FierceBiotech.com) +36.91%
08:00AM	Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals (Business Wire)
Feb-05-24 08:00AM	Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (Business Wire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.91%
Jan-04-24 08:00AM	Immunome Appoints Phil Roberts as Chief Technical Officer (Business Wire)
Jan-03-24 08:00AM	Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.27%
Jan-02-24 08:00AM	Immunome Appoints Carol A. Schafer to Board of Directors (Business Wire)
Dec-26-23 08:30AM	Immunome to Acquire Antibody-Related Assets and Materials from Atreca (Business Wire) +8.20%
08:30AM	Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome (GlobeNewswire)
Nov-10-23 08:00AM	Immunome to Present at the Stifel 2023 Healthcare Conference (Business Wire) -5.49%
Nov-09-23 08:00AM	Immunome Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-08-23 08:00AM	Immunome Appoints Jean-Jacques Bienaim to Board of Directors (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-19-23 08:00AM	Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer (Business Wire)
Oct-04-23 11:00PM	Insider Buying: Immunome Inc's President and CEO Clay Siegall Acquires 169,204 Shares (GuruFocus.com)
Oct-03-23 08:00AM	Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies (Business Wire)
Aug-17-23 08:19PM	Inside the deal: How Immunome and MophImmune came to a merger agreement (American City Business Journals)
Aug-09-23 08:00AM	Immunome Reports Second Quarter 2023 Financial Results (Business Wire)
Jun-30-23 09:51AM	Immunome (IMNM) Surges on Merger Agreement With Morphimmune (Zacks)
Jun-29-23 09:00AM	Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies (PR Newswire) +30.29%
Jun-02-23 07:55AM	Immunome's (NASDAQ:IMNM) investors will be pleased with their favorable 45% return over the last year (Simply Wall St.)
May-23-23 04:05PM	Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity (Business Wire) +11.57%
May-09-23 08:50AM	Here's What Could Help Immunome, Inc. (IMNM) Maintain Its Recent Price Strength (Zacks) +8.51%
May-05-23 08:00AM	Immunome Reports First Quarter 2023 Financial Results (Business Wire)
Apr-20-23 08:50AM	Immunome, Inc. (IMNM) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Mar-16-23 08:00AM	Immunome Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire) +9.24%
Mar-13-23 07:32AM	Immunome, Inc.'s (NASDAQ:IMNM) Shift From Loss To Profit (Simply Wall St.)
Mar-09-23 08:45AM	Immunome to Present at 13th Annual World ADC London Conference (Business Wire)
Feb-08-23 08:00AM	Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board (Business Wire)
Jan-31-23 06:52AM	Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-06-23 04:05PM	AbbVie Briefly Breaks Out After Tapping Immunome In $30 Million Cancer Deal (Investor's Business Daily) -15.47%
02:46PM	Immunome enters into a cancer drug collaboration with AbbVie worth up to $2.8B (American City Business Journals)
10:35AM	Immunome Stock Jumps On Discovery Pact With AbbVie (Benzinga)
08:00AM	AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets (PR Newswire)
Nov-14-22 08:00AM	Immunome Reports Third Quarter 2022 Financial Results (Business Wire)
Nov-09-22 12:00PM	Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (Business Wire)
Oct-04-22 06:08AM	Immunome, Inc.'s (NASDAQ:IMNM) Shift From Loss To Profit (Simply Wall St.)
Aug-24-22 06:59AM	Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation (Simply Wall St.)
Aug-23-22 09:00AM	Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer (Business Wire) +5.96%
Aug-05-22 08:00AM	Immunome Reports Second Quarter 2022 Financial Results (Business Wire) +17.41%
Jul-06-22 09:28AM	Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants (Benzinga) +12.57%
08:00AM	Immunomes COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1 (Business Wire)
Jun-09-22 08:00AM	Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19 (Business Wire)
Jun-02-22 08:00AM	Immunome to Present at the Jefferies Healthcare Conference (Business Wire)
May-26-22 08:07AM	Immunome, Inc. (NASDAQ:IMNM) insider upped their holding by earlier this year (Simply Wall St.) +8.33%
May-23-22 08:00AM	Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38 (Business Wire)
May-19-22 03:27PM	Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data (Benzinga) +17.96%
11:31AM	Immunome shares soar on positive testing data for its experimental Covid therapy (American City Business Journals)
08:00AM	Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant (Business Wire)
May-12-22 08:00AM	Immunome Reports First Quarter 2022 Financial Results (Business Wire) +10.43%
Mar-28-22 08:00AM	Immunome Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +23.03%

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIEGALL CLAY B	President and CEO	Nov 21 '24	Buy	9.54	66,057	630,263	485,693	Nov 25 08:41 AM
SIEGALL CLAY B	President and CEO	Nov 22 '24	Buy	9.78	33,943	331,918	519,636	Nov 25 08:41 AM
Lechleider Robert	Chief Medical Officer	Nov 21 '24	Buy	9.48	15,805	149,800	15,805	Nov 25 08:35 AM
Tsai Philip	Chief Technology Officer	Nov 21 '24	Buy	9.43	21,000	198,030	21,000	Nov 25 08:33 AM
Rosett Max	Chief Financial Officer	Sep 19 '24	Option Exercise	1.05	42,000	44,100	61,856	Sep 20 07:26 PM
Rosett Max	Chief Financial Officer	Sep 19 '24	Sale	16.01	14,380	230,224	47,476	Sep 20 07:26 PM
Rosett Max	Officer	Sep 19 '24	Proposed Sale	16.01	14,380	230,211		Sep 19 02:18 PM
BIENAIME JEAN JACQUES	Director	Aug 16 '24	Buy	13.94	7,000	97,608	16,615	Aug 19 09:07 PM
Higgins Jack	Chief Scientific Officer	Aug 15 '24	Option Exercise	1.35	19,524	26,357	19,524	Aug 19 09:05 PM
Higgins Jack	Chief Scientific Officer	Aug 15 '24	Sale	13.93	3,524	49,072	16,000	Aug 19 09:05 PM
Higgins Jack	Officer	Aug 15 '24	Proposed Sale	13.93	3,524	49,073		Aug 15 03:21 PM
BIENAIME JEAN JACQUES	Director	May 21 '24	Buy	13.57	2,000	27,140	9,615	May 22 04:49 PM
SIEGALL CLAY B	President and CEO	May 20 '24	Buy	13.91	79,566	1,106,524	399,202	May 21 04:13 PM
SIEGALL CLAY B	President and CEO	May 21 '24	Buy	13.78	20,434	281,548	419,636	May 21 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNM

Immunome Inc

Upgrade your FINVIZ experience